OBI Pharma Enrolls Phase 2/Phase 3 Clinical Trial of OBI-822 Metastatic Breast Cancer Immunotherapy Drug

OBI Pharma Enrolls Phase 2/Phase 3 Clinical Trial of OBI-822 Metastatic Breast Cancer Immunotherapy Drug
OBI Pharma, Inc., a Taiwan-based biotech company developing novel therapeutic agents for unmet medical needs, has completed patient enrollment in its Phase 2/3 randomized double-blind controlled trial assessing the safety and efficacy of OBI-822, an active immunotherapy for the treatment of metastatic breast cancer. The compound is exclusively licensed to OBI by the Memorial Sloan-Kettering Cancer Center.

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *